This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.The purpose of this study is to determine if blood and lymph node cells from cancer patients can be simulated in the laboratory with a vaccine to react with p53, a protein found in tumor cells. The study is designed to evaluate the ability of an experimental vaccine to stimulate immune responses against p53, a protein which is found in abundance in many cancers. The vaccine to be tested is composed of a virus known as modified vaccinia virus Ankara. This virus has been genetically manipulated in the laboratory to produce the p53 protein. Immune cells exposed to this vaccine develop reactivity towards the cells, including tumor cells, which contain the p53 protein. The experiments performed on the blood and the lymph node cells used in this trial will help determine the feasibility of embarking upon a future vaccine trial involving the administration of the experimental vaccine product to patients with cancer.
Showing the most recent 10 out of 565 publications
